Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will present at three investor conferences in September 2026: the Morgan Stanley Global Healthcare Conference on September 14, the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will present at three investor conferences in September 2026: the Morgan Stanley Global Healthcare Conference on September 14, the J.P. Morgan U.S. All Stars Conference on September 22, and the BofA Global Healthcare Conference on September 23. Live webcasts and archives will be available via Teva’s Investor Relations website.
Details
News Market Reaction – TEVA
On Sep 2, the first trading day after this news, TEVA closed 3.54% above the previous close. Our momentum scanner recorded 13 alerts for this stock that day. Relative volume reached 41.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Investor conferences
- 3 conferences
- September 2026
- Morgan Stanley conference
- September 14, 2026
- 8:30 A.M. Eastern Time
- J.P. Morgan conference
- September 22, 2026
- 8:00 A.M. British Summer Time
- BofA conference
- September 23, 2026
- 10:55 A.M. British Summer Time
- Webcast archive
- 24 hours
- Availability after the live discussion
Historical Context
-
Proposed BioXcel neuroscience asset acquisition faced auction and approval conditions.
-
FDA accepted ecopipam’s NDA and granted Priority Review for pediatric Tourette syndrome.
-
Moody’s upgraded Teva to investment grade with a stable outlook.
-
UZEDY sales reached $77 million and Teva raised its 2026 revenue outlook.
-
UZEDY sales growth supported a higher 2026 revenue outlook from Teva.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at three upcoming investor conferences in September as follows:
- Morgan Stanley 24th Annual Global Healthcare Conference
Monday, September 14, 2026, at 8:30 A.M. Eastern Time (ET) - J.P. Morgan U.S. All Stars Conference
Tuesday, September 22, 2026, at 8:00 A.M. British Summer Time (3:00 A.M. ET) - BofA Global Healthcare Conference 2026
Wednesday, September 23, 2026, at 10:55 A.M. British Summer Time (5:55 A.M. ET)
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Document and the presentation at the conferences may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors,” “Other Information” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.